Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511845 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Chugai Pharmaceutical.
- Active
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 15
- Study locations
NCT04511845 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Chugai Pharmaceutical. The registered enrollment target is 113 participants, below the 276-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (59% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT04511845, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Chugai Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase I, open-label, multi-center study
Conditions Studied
Interventions
- DRUG SPYK04
Study Locations (15)
Texas
- MD Anderson Cancer Center - Houston
- Texas Oncology - Tyler
Virginia
- University of Virginia - Charlottesville
- Virginia Cancer Specialists - Fairfax
Tokyo
- National Cancer Center Hospital - Chuo Ku
- Cancer Institute Hospital of Japanese Foundation for Cancer Research - Koto-Ku
Other
- National Hospital Organization Kyushu Cancer Center - Fukuoka
- Osaka Prefectural Hospital Organization Osaka International Cancer Center - Osaka
Arizona
- Arizona Oncology - Tucson
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Minnesota
- Minnesota Oncology - Minneapolis
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04511845
The ClinicalTrials.gov registry entry for NCT04511845 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 276-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (59% lower). The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SPYK04 is the first listed.
NCT04511845 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Texas, Virginia, Tokyo.
Frequently Asked Questions
What is clinical trial NCT04511845 about?
NCT04511845 is a clinical study titled "A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).". Phase I, open-label, multi-center study
What is the current status of trial NCT04511845?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2020-09-10. Estimated completion is 2026-09-30.
What conditions does trial NCT04511845 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT04511845?
The interventions under investigation include: SPYK04 (DRUG).
Who is sponsoring clinical trial NCT04511845?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04511845 being conducted?
This trial has 15 study locations across Arizona, Colorado, Minnesota, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.